Status:
COMPLETED
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Lead Sponsor:
Allergan
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
Eligibility Criteria
Inclusion
- If female, must be of nonreproductive potential
- If male, must agree to use acceptable contraception
- Symptoms of overactive bladder with urinary urgency incontinence
- Inadequate response or limiting side effects with anticholinergics for the treatment of OAB
Exclusion
- Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple sclerosis)
- History of bladder surgery
- Treatment with botulinum toxin therapy of any serotype for any non-urological condition within the prior 12 weeks
- Previous treatment with botulinum toxin therapy of any serotype for any urological condition
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01157377
Start Date
October 1 2010
End Date
May 1 2013
Last Update
March 19 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Richmond, Virginia, United States
2
Lyon, France
3
Amsterdam, Netherlands